Europe’s cocaine story is not moving in one direction everywhere. A March 2026 release reported higher residues across comparable European cities. A separate English analysis published the following month showed a decline in its 2025 observation, while remaining above an earlier baseline. Both can be true. The difference is a reason to investigate, not to choose the more dramatic headline.
Key findings
Nearly 22%: EUDA’s reported increase in cocaine residues between 2024 and 2025 in its comparable-city analysis.
48 increased, 21 were stable, and 16 decreased: the breakdown among 85 cities with observations in both years.
4,975 to 4,045 milligrams per 1,000 people per day: the change between the January to April 2024 and 2025 observations at 16 consistently sampled English sites.
18.7%: THE BALANCE’s calculated decline between those two English point estimates.
The European and English programs use different catchments, periods, and methods. Their percentages are not a direct country ranking. [1] [2]
A regional increase did not mean every city increased
Source: EUDA/SCORE, March 18, 2026. Change categories retain the source’s definitions and the cocaine-specific comparison set. [1]
The city breakdown adds information that the regional headline cannot provide. A broad increase can coexist with stable or declining observations elsewhere. It does not support a claim that every European city experienced the same change or that local treatment need rose by an identical percentage.
The starting year changes the English story
The English 2025 point estimate remained above 3,206 in 2021, despite falling from the 2024 estimate. A longer-term increase and a 2024-to-2025 decline are therefore both accurate descriptions of this series. Neither should be hidden to produce a simpler narrative. [2]
| January to April observation | mg per 1,000 people per day | Published standard error of the mean (SEM) |
|---|---|---|
| 2021 | 3,206 | 109 |
| 2022 | 4,164 | 62 |
| 2023 | 4,328 | 156 |
| 2024 | 4,975 | 201 |
| 2025 | 4,045 | 98 |
Source: Home Office WAND, Table 2, updated October 8, 2026. The series covers 16 consistently sampled treatment-plant catchments, not national-scale estimates. Estimates represent street-drug volume after retail-purity adjustment. Its revised method supersedes the March 2025 figures. [2]
The 2025 observation fell from 2024 but remained above the 2021 baseline. The point estimates do not identify the cause. Source: Home Office WAND’s revised 2026 series. [2]
These are not competing verdicts on the same population
The European program compares residues across participating cities. The English series estimates consumption using a specified model and consistent sites. Sampling periods, coverage, and methods differ. Putting the two headline percentages on a single axis as equivalent national measures would distort the comparison.
The contrast still has value. It shows why regional averages and more specific observations can move differently. A useful next investigation would look for compatible observations and ask whether surveys, treatment presentations, or other evidence support the pattern. Each additional source would need its own scope and limitations.
A declining wastewater estimate does not show that a country solved cocaine-related harm. A regional increase does not establish an identical rise everywhere. Monitoring should inform the investigation rather than replace it.
A financial center is not a sample of financiers
The UK, Switzerland, Germany, and the Netherlands include places where internationally mobile professionals live and work. That makes the geography relevant to THE BALANCE’s audience. It does not establish who contributed to the wastewater measurements.
A catchment can include residents, commuters, visitors, and nightlife activity. Wastewater cannot identify someone’s job, assets, or diagnosis. It cannot distinguish individual occasional use from a use disorder, or show that bankers and founders caused a high measured load. The Home Office explicitly notes the inability to assign consumption to individuals. [2]
The useful client angle is assessment and care. How should concerns be evaluated? What evidence supports the proposed treatment? What will be measured afterward? Speculating about the private behavior of a professional group adds drama without adding evidence.
The best-supported response is not necessarily the newest
A 2021 systematic review and meta-analysis included 157 clinical trials and 15,842 adult outpatients actively using cocaine. Contingency-management programs were associated with greater odds of a cocaine-negative urine result at the end of treatment compared with baseline: pooled odds ratio 2.13, with a 95% confidence interval of 1.62 to 2.80. This was not a direct contingency-management-versus-control comparison. The search covered studies published through 2017. [3]
That result concerns a specified test outcome in a historical evidence synthesis. It is not a permanent-recovery rate or a statement that 213% of people recovered. An odds ratio is not the same as a direct percentage-point increase in the chance of recovery.
For a family evaluating an extensive private program, the question is which components have evidence relevant to cocaine-use difficulties. The service should explain their delivery, intended role, and outcome measures. An impressive setting or novel technique does not answer those questions on its own.
What outcomes should be followed
A meaningful report distinguishes use, periods without use, harms, disorder symptoms, and daily functioning. It explains whether substance use was measured through self-report, biological testing, or both. The observation period and number with follow-up belong beside the result.
Returning to meetings does not establish the absence of a disorder. Equally, temporarily reducing responsibilities can be compatible with progress. For a person in a demanding role, goals should be clinically appropriate and agreed rather than reduced to immediate restored performance.
Other substances and conditions may also need assessment. One positive test or one disclosed substance should not automatically be treated as the explanation for every difficulty. Where several clinicians are involved, the plan should make coordination and follow-up responsibilities clear.
| Evidence | Question answered | Not established alone |
|---|---|---|
| Wastewater | Change in covered catchments | Individual users, wealth, or diagnoses |
| Treatment-service records | Who entered a defined service | Need in the whole population |
| Outcome research | Change among studied participants | Results of an unrelated clinic’s program |
Why the dates belong in the story
The European release appeared in March 2026 and concerned 2025 sampling. The English report was published on April 13, 2026, amended on June 12 and updated on October 8. This article compares its 2024 and 2025 observations. A separate Home Office report published on October 14, 2026 extends the trend series to 2026, so the 2025 observation is not the latest available. A quarterly briefing can cover those releases, but should not call the observations cocaine use during those publication quarters.
Revisions matter in historical comparisons too. A retrospective can use revised estimates when it says so. It should not compare an older release’s value with a revised value and present the difference as a real change in consumption.
For journalists, the strongest comparative question is therefore where the pattern differs after aligning methods and periods. A city ranking should not be created merely because different programs publish numbers with similar-looking units.
What families can ask before choosing care
Ask which evidence supports the intervention being offered and whether that evidence matches the person’s needs. Then ask how the service measures progress, what happens when treatment changes, and how it accounts for people not reached at follow-up. A success percentage without those details is difficult to interpret.
For internationally mobile patients, clarify who receives the treatment record and who remains responsible after travel or discharge. This is a planning question, not a finding that a particular country or group has worse coordination. The monitoring data cannot answer it.
Acute chest pain, seizures, severe agitation, or loss of consciousness require urgent medical attention. Population research and comparisons between treatment approaches are not substitutes for emergency assessment when someone is acutely unwell.
What the numbers cannot tell us
The monitoring programs do not identify affluent users, addiction prevalence, or a provider’s treatment results. Their different headline changes cannot be pooled into a single regional score. The calculated English decline uses point estimates and does not add a new uncertainty interval for that change.
The treatment review does not validate every private program or establish permanent recovery. Its outcome, comparator, and evidence-search period remain part of the claim.
The bottom line
The English counterpoint makes the European story more informative, not less important. It replaces a uniform narrative with questions about location, timing, and method. For families, the next step is an appropriate assessment and an inspectable treatment plan, not a stereotype about a city or profession.
For journalists
Key contrast: nearly 22% higher residues in EUDA’s comparable-city analysis, alongside an 18.7% calculated decline in the English consistent-site point estimate.
Important caveat: these are different monitoring programs, not directly comparable national performance scores.
Suggested attribution: THE BALANCE comparison of EUDA/SCORE and Home Office wastewater findings.
Methodology and sources
The English percentage is calculated as (4,045 divided by 4,975, minus 1) multiplied by 100, rounded to one decimal place. Published standard errors of the mean are retained; these are not 95% confidence intervals. The programs are not pooled, and no individual or provider data were analyzed.


